华森制药收到药品再注册批准通知书

Core Viewpoint - Huason Pharmaceutical (002907.SZ) has received approval from the Chongqing Municipal Drug Administration for the re-registration of two pharmaceutical products: Glycyrrhizic Acid Dipotassium Salt and Sodium Ferulate Injection [1] Group 1: Product Approvals - The company has been granted a re-registration approval notice for Glycyrrhizic Acid Dipotassium Salt, which is a raw material used for producing Glycyrrhizic Acid Dipotassium Salt Injection [1] - The Sodium Ferulate Injection, which is used as an auxiliary treatment for ischemic cardiovascular and cerebrovascular diseases, has also received re-registration approval [1]